Uro-oncological pathology tutorial: a 3-day "meet the expert"
24th – 26th November, 2016

This 2-and-half-day Tutorial aims to cover the main current issues in the pathology of human prostate and bladder cancers: Theoretical presentations will include normal macroscopy and microscopy, diagnostic criteria, prognosis evaluation, histological subtypes, diagnostic pitfalls, specimen handling and report. Practical clinicopathological cases will support discussion and ensure interactivity. The final sessions will focus on molecular pathology, translational research and perspectives for the future regarding molecular biomarkers, tumor classification, and the implications for clinical trial design. The course will be in English language and of interest for pathologists and other physicians or researchers involved in the field.

Yves Allory is professor of Pathology at Henri Mondor Hospital and University Paris Est (Créteil, France). He has a 15 year experience in Genito-Urinary Pathology, with a strong interest in research for bladder and prostate cancer biomarkers and classifications. He is member of the board of EAU Section of Urological Research (ESUR).

Ferran Algaba is the chief of Pathology Department of Fundació Puigvert and associated professor of Universitat Autònoma de Barcelona (Spain). He has 40 years of experience in genito-urinary pathology and is member of the WHO, UICC, ISUP and European societies of Pathology and Urology.

Francisco X. Real is group leader at the Epithelial Carcinogenesis Group, CNIO, and Professor of Cell Biology at Universitat Pompeu Fabra (Barcelona, Spain). His group works on the molecular cell biology of pancreatic and bladder cancer combining cell culture, genetic mouse models, and patient studies. He is Associate Editor of the journal "Bladder Cancer".

David Olmos is group leader at the Prostate Cancer Clinical Research Unit, CNIO, and is a co-Director of the CNIO Associated Clinical Unit at the Hospital Virgen de la Victoria (Málaga, Spain). His group works does translational research and clinical trials in prostate cancer.

The fees are 150 € (RTICC members, free). They include printed resources, meals, and coffee breaks.
Thursday 24th November 2016

Prostate Cancer

9:00-9:15 Welcome and presentation of the 3-day course and participants (FXR)
9:15-9:35 Normal prostate. Zonal anatomy and functional histology of prostate
9:35-10:00 Diagnostic criteria for the acinar prostate adenocarcinoma
10:00-10:30 Seminar cases (diagnosis)
10:30-11:00 Prognosis parameters on needle core biopsies

11:00-11:30 Coffee break

11:30-12:00 Seminar cases (prognosis on biopsies)
12:00-12:30 Prognosis parameters on radical prostatectomies
12:30-13:00 Seminar cases (prognosis on surgical specimen)
13:00-13:30 Non-acinar prostate carcinoma (histological subtypes)

13:30-14:30 Lunch

14:30-15:00 CNIO visit
15:00-15:45 Seminar cases (histological subtypes)
15:45-16:30 Diagnostic pitfalls

16:30-17:00 Coffee break

17:00-17:30 Seminar cases (diagnostic pitfalls)
17:30-18:00 Specimen handling and report
Friday 25th November 2016

Bladder Cancer

9:00-9:30 Normal urinary bladder Variability and function
9:30-9:45 Diagnostic criteria of urothelial cell carcinoma
9:45-10:15 Prognostic parameters on TURB (stage and grade)
10:15-11:00 Seminar cases (diagnosis)

11:00-11:30 Coffee break

11:30-12:15 Prognosis parameters on cystectomy and seminar cases
12:15-13:00 Histological variants
13:00-13:30 Seminar cases (histological variants)

13:30-14:30 Lunch

14:30-15:15 Seminar cases (histological variants)
15:15-16:00 Diagnostic pitfalls (Pseudotumors)

16:00-16:30 Coffee break

16:30-17:00 Seminar cases (diagnostic pitfalls)
17:00-17:30 Specimen handling and report of TURB and cystectomy
17:30-18:00 Evaluation test
### Saturday 26th November 2016

**Molecular pathology and clinical trials in prostate and bladder cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-9:45</td>
<td>Molecular classification and heterogeneity in prostate cancer</td>
</tr>
<tr>
<td>9:45-10:30</td>
<td>Molecular classification and heterogeneity in bladder cancer</td>
</tr>
<tr>
<td><strong>10:30-11:00</strong></td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>11:00-11:45</td>
<td>New preclinical models in bladder and prostate cancer</td>
</tr>
<tr>
<td>11:45-12:15</td>
<td>Current and future clinical trials in prostate cancer</td>
</tr>
<tr>
<td>12:15-12:45</td>
<td>Current and future clinical trials in bladder cancer</td>
</tr>
<tr>
<td>12:45-13:30</td>
<td>Molecular biomarkers: recommendations in 2016 and perspectives</td>
</tr>
</tbody>
</table>